Epsilogen: co-opting IgE antibodies against cancer

Epsilogen is taking a long overlooked isotype of human antibodies -- the IgE class -- and leveraging their high affinity for immune effector cells to seek out and destroy solid tumors.

“What we are doing is we are redirecting the tropism of a major arm of the immune system,” CEO Tim Wilson told BioCentury...